82.11
0.66 (0.81%)
| Previous Close | 81.45 |
| Open | 81.05 |
| Volume | 732,483 |
| Avg. Volume (3M) | 1,081,683 |
| Market Cap | 5,247,321,600 |
| Price / Sales | 10.06 |
| Price / Book | 17.43 |
| 52 Weeks Range | |
| Earnings Date | 30 Apr 2025 - 5 May 2025 |
| Profit Margin | -13.19% |
| Operating Margin (TTM) | -28.15% |
| Diluted EPS (TTM) | -1.07 |
| Quarterly Revenue Growth (YOY) | 103.40% |
| Total Debt/Equity (MRQ) | 242.51% |
| Current Ratio (MRQ) | 2.85 |
| Operating Cash Flow (TTM) | -192.59 M |
| Levered Free Cash Flow (TTM) | -76.03 M |
| Return on Assets (TTM) | -11.89% |
| Return on Equity (TTM) | -31.26% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Blueprint Medicines Corporation | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 3.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | 1.50 |
|
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.87% |
| % Held by Institutions | 106.72% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 150.00 (Scotiabank, 82.68%) | Buy |
| Median | 128.50 (56.50%) | |
| Low | 100.00 (Morgan Stanley, 21.79%) | Hold |
| Average | 127.90 (55.77%) | |
| Total | 8 Buy, 2 Hold | |
| Avg. Price @ Call | 93.28 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wedbush | 16 Apr 2025 | 128.00 (55.89%) | Buy | 80.98 |
| Needham | 08 Apr 2025 | 133.00 (61.98%) | Buy | 79.22 |
| 14 Feb 2025 | 133.00 (61.98%) | Buy | 93.94 | |
| Morgan Stanley | 20 Mar 2025 | 100.00 (21.79%) | Hold | 88.47 |
| Jefferies | 17 Mar 2025 | 135.00 (64.41%) | Buy | 92.14 |
| Scotiabank | 07 Mar 2025 | 150.00 (82.68%) | Buy | 87.12 |
| Citizens Capital Markets | 03 Mar 2025 | 125.00 (52.23%) | Buy | 89.75 |
| HC Wainwright & Co. | 14 Feb 2025 | 135.00 (64.41%) | Buy | 93.94 |
| JMP Securities | 14 Feb 2025 | 125.00 (52.23%) | Buy | 93.94 |
| JP Morgan | 04 Feb 2025 | 129.00 (57.11%) | Buy | 113.40 |
| Piper Sandler | 27 Jan 2025 | 119.00 (44.93%) | Hold | 113.88 |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 31 Mar 2025 | Announcement | Blueprint Medicines to Present at 24th Annual Needham Virtual Healthcare Conference |
| 28 Feb 2025 | Announcement | Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress |
| 13 Feb 2025 | Announcement | Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results |
| 05 Feb 2025 | Announcement | Blueprint Medicines to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |